Results 201 to 210 of about 3,144,476 (264)

Changes in Components of Sarcopenia Diagnostic Criteria Throughout the Surgical Treatment of Oesophagogastric Cancer Surgery: A Prospective Longitudinal Study

Journal of Human Nutrition and Dietetics, Volume 39, Issue 1, February 2026.
ABSTRACT Introduction Low skeletal muscle is prevalent and associated with poorer outcomes after oesophagogastric (OG) cancer surgery. However, sarcopenia, including strength and function, is less commonly assessed. Therefore, we aimed to describe the prevalence of sarcopenia and changes in diagnostic criteria within 1 year of OG cancer surgery ...
Lisa C. Murnane, Adrienne K. Forsyth, Jim Koukounaras, Kalai Shaw, Eldho Paul, Wendy A. Brown, Audrey C. Tierney, Paul R. Burton   +7 more
wiley   +1 more source

Biochemical and Physiological Effects of Galanin in Health and Disease

The FASEB Journal, Volume 40, Issue 2, 31 January 2026.
Galanin is a biologically active neuropeptide hormone that mediates its effects through three galanin receptors. Galanin signaling induces changes in glucose homeostasis amongst others and plays a dynamic role in the physiological health of many organ systems.
Patrick Mireles, Yubo Wang, Kathryn Rhodes, Sharon DeMorrow   +3 more
wiley   +1 more source

Targeting the <i>ZMYM2-ANXA9</i> Axis: Organoid Models Illuminate a Novel Pathway to Overcome Oxaliplatin Resistance in Colorectal Cancer. [PDF]

Biomedicines
Zeng SJ, He K, Shi Z.
europepmc   +1 more source

KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer. [PDF]

Cancer Drug Resist
Xu Z, Sun S, Gao H, Feng R, Shen X.
europepmc   +1 more source

Correction: An integrative analysis of transcriptome, methylome and single-cell RNA sequencing data identifies UBE2H as a marker of oxaliplatin resistance in colorectal cancer. [PDF]

Cancer Cell Int
Fang J, Zhu Q, Hong B, Li X, Wang H.
europepmc   +1 more source

Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat. [PDF]

Oncol Rep
Röttgen H, Theurer L, Peccerella T, Sandu K, Weiss J, Burhenne J, Neoptolemos JP, Köberle B, Theile D.   +8 more
europepmc   +1 more source

Cigarette smoke extract promotes metastasis and oxaliplatin resistance in colon adenocarcinoma through GDF15/ERBB2/AKT pathway. [PDF]

Eur J Med Res
Jiang W, Wang Y, Wang WJ, Zhou BC, Hu XS, Xu AM.   +5 more
europepmc   +1 more source

An integrative analysis of transcriptome, methylome and single-cell RNA sequencing data identifies UBE2H as a marker of oxaliplatin resistance in colorectal cancer. [PDF]

Cancer Cell Int
Fang J, Zhu Q, Hong B, Li X, Wang H.
europepmc   +1 more source

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer using Oxaliplatin and Coxsackievirus A11

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer using Oxaliplatin and Coxsackievirus A11
Background: Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is the third most common cancer worldwide and the fourth most common cause of cancer-related death. FOLFOX, a combination of leucovorin calcium, fluorouracil, and oxaliplatin, is the first-line chemotherapy for stage III and stage IV CRC.
openaire  

Overexpression of Protein Kinase C iota as a prognostic marker and its role in oxaliplatin resistance in colorectal cancer. [PDF]

BMC Gastroenterol
Liao X, Liu M, Hong C, Liu Y, Li Q, Chen Y, Zhang T, Chen H, Fu S.   +8 more
europepmc   +1 more source